Insight Molecular Diagnostics Inc. (IMDX) Gamma Exposure (GEX) & Greeks
Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $136.9M, listed on NASDAQ, employing roughly 46 people, carrying a beta of 1.63 to the broader market. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. Led by Joshua Riggs, public since 2015-12-30.
Snapshot as of May 15, 2026.
- Spot Price
- $6.37
- Net Gamma
- -$930
- Net Delta
- -$292.2K
- Net Vega
- -$764
- Gamma Concentration
- 0.42
As of May 15, 2026, Insight Molecular Diagnostics Inc. (IMDX) has negative net gamma exposure of $930 under the standard dealer-hedging convention. Net delta exposure is -$292.2K. Negative GEX means dealers are net short gamma: they must sell into weakness and buy into strength, amplifying realized volatility and accelerating directional moves.
IMDX Strategy Sizing in the Current GEX Regime
Insight Molecular Diagnostics Inc. is in a negative dealer-gamma regime ($930). Net dealer delta of -$292.2K sets the size of the directional hedging flow that fires as spot moves. In this regime, momentum and breakout strategies fit the regime: long calls or puts, ratio backspreads, calendar spreads positioned for vol expansion. Realized volatility tends to overshoot implied during negative-gamma stretches, hurting indiscriminate short-vol exposure. The gamma-flip level - the spot price at which net dealer gamma changes sign - is the most actionable anchor for sizing: through-flip moves trigger qualitatively different hedging behavior than within-regime moves, so risk-defined structures sized to the current spot may not stay sized correctly if a flip is near.
Learn how gamma exposure is reported and how to read the data →
Frequently asked IMDX gamma exposure (gex) & greeks questions
- What is the current IMDX gamma exposure (GEX)?
- As of May 15, 2026, Insight Molecular Diagnostics Inc. (IMDX) net gamma exposure is negative at $930 under the standard dealer-hedging convention. Net dealer delta exposure is -$292.2K. GEX aggregates the gamma sitting on dealer books across all listed strikes and expirations.
- Is IMDX in positive or negative dealer gamma right now?
- IMDX is currently in negative dealer gamma. Dealers net short gamma must sell into weakness and buy into strength to maintain delta-neutrality, which amplifies realized volatility and tends to accelerate directional moves.
- What does IMDX GEX tell options traders?
- GEX is a regime indicator: positive-gamma regimes favor mean-reverting strategies (premium-selling near established ranges); negative-gamma regimes favor momentum and breakout strategies. The same options-strategy structure can be appropriate or inappropriate depending on the dealer-gamma regime, so reading the sign and magnitude of net GEX before sizing positions is standard practice.